These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8021707)

  • 1. Saul R. Korey Lecture. Molecular genetics of Tay-Sachs and related disorders: a personal account.
    Suzuki K
    J Neuropathol Exp Neurol; 1994 Jul; 53(4):344-50. PubMed ID: 8021707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
    Gort L; de Olano N; Macías-Vidal J; Coll MA;
    Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
    Suzuki K; Vanier MT
    Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-hexosaminidase: biosynthesis and processing of the normal enzyme, and identification of mutations causing Jewish Tay-Sachs disease.
    Mahuran DJ
    Clin Biochem; 1995 Apr; 28(2):101-6. PubMed ID: 7628066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tay-Sachs disease].
    Tanaka A
    Nihon Rinsho; 1993 Sep; 51(9):2281-5. PubMed ID: 8411703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathogenic HEXA missense variant in wild boars with Tay-Sachs disease.
    Bertani V; Prioni S; Di Lecce R; Gazza F; Ragionieri L; Merialdi G; Bonilauri P; Jagannathan V; Grassi S; Cabitta L; Paoli A; Morrone A; Sonnino S; Drögemüller C; Cantoni AM
    Mol Genet Metab; 2021 Jul; 133(3):297-306. PubMed ID: 34119419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
    Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
    Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.
    Maegawa GH; Stockley T; Tropak M; Banwell B; Blaser S; Kok F; Giugliani R; Mahuran D; Clarke JT
    Pediatrics; 2006 Nov; 118(5):e1550-62. PubMed ID: 17015493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease.
    Vu M; Li R; Baskfield A; Lu B; Farkhondeh A; Gorshkov K; Motabar O; Beers J; Chen G; Zou J; Espejo-Mojica AJ; Rodríguez-López A; Alméciga-Díaz CJ; Barrera LA; Jiang X; Ory DS; Marugan JJ; Zheng W
    Orphanet J Rare Dis; 2018 Sep; 13(1):152. PubMed ID: 30220252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
    Kissell J; Rochmann C; Minini P; Eichler F; Stephen CD; Lau H; Toro C; Johnston JM; Krupnick R; Hamed A; Cox GF
    Mol Genet Metab; 2024 Jul; 142(3):108512. PubMed ID: 38870773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.
    Yamanaka S; Johnson MD; Grinberg A; Westphal H; Crawley JN; Taniike M; Suzuki K; Proia RL
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9975-9. PubMed ID: 7937929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics and Therapies for GM2 Gangliosidosis.
    Cachon-Gonzalez MB; Zaccariotto E; Cox TM
    Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
    Seyrantepe V; Demir SA; Timur ZK; Von Gerichten J; Marsching C; Erdemli E; Oztas E; Takahashi K; Yamaguchi K; Ates N; Dönmez Demir B; Dalkara T; Erich K; Hopf C; Sandhoff R; Miyagi T
    Exp Neurol; 2018 Jan; 299(Pt A):26-41. PubMed ID: 28974375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GM2-gangliosidoses and the elucidation of the beta-hexosaminidase system.
    Sandhoff K
    Adv Genet; 2001; 44():67-91. PubMed ID: 11597000
    [No Abstract]   [Full Text] [Related]  

  • 20. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
    Igdoura SA; Mertineit C; Trasler JM; Gravel RA
    Hum Mol Genet; 1999 Jun; 8(6):1111-6. PubMed ID: 10332044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.